Theratechnologies Inc.

TH

CA88338H7040

Pharmaceuticals

Market Closed - Toronto S.E. Other stock markets 20:59:29 15/07/2024 BST			5-day change	1st Jan Change
2.11 ^CAD	+7.11%		+11.05%	-1.40%

07-10	Theratechnologies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2024	CI
07-10	Transcript : Theratechnologies Inc., Q2 2024 Earnings Call, Jul 10, 2024

Theratechnologies Reports on its Annual Meeting of Shareholders

May 09, 2024 at 10:27 pm

On May 29, 2024, Theratechnologies Inc announced the voting results of its Annual General Meeting (AGM) of shareholders held on May 29, 2024. Since no further discussions have occurred between Soleus Capital Management, L.P and the Company, the campaign is considered to have been withdrawn.

Latest news about Theratechnologies Inc.

Theratechnologies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2024	07-10	CI
Transcript : Theratechnologies Inc., Q2 2024 Earnings Call, Jul 10, 2024	07-10
Theratechnologies Swings to Q2 Profit as Revenue Rises 25%; Confirms FY24 Guidance	07-10	MT
Theratechnologies Brief: Fiscal 2024 revenue guidance confirmed between US$87 and $90 million and an Adjusted EBITDA in the range of $13 to $15 million	07-10	MT
Theratechnologies Brief: Positive net income of US$1 million realized with Adjusted EBITDA of $5.5 million For Q2	07-10	MT
Theratechnologies Brief: Q2 Revenue of US$22 million represents 25% growth year-over-year	07-10	MT
Theratechnologies Inc. Provides Earnings Guidance for the Year 2024	07-10	CI
North American Morning Briefing : Powell's Second Day of Remarks Awaited	07-10	DJ
Theratechnologies Up Near 5% In US After Hours On Data Related To Its Lead Investigational Peptide Drug Conjugate Candidate	05-23	MT
Theratechnologies Brief: Says Sudocetaxel Zendusortide ASCO 2024 Presentation "Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors"	05-23	MT
Theratechnologies Reports on its Annual Meeting of Shareholders	05-09	CI
Theratechnologies Inc. Announces Frank Holler as Chair of the Board of Directors	05-09	CI
Transcript : Theratechnologies Inc. - Shareholder/Analyst Call	05-09
Update On Theratechnologies; Down More Than 5% On TSX As Q1 Net Loss Narrows, Awaits FDA Decision	04-10	MT
Theratechnologies Up Near 6% In US Premarket As Q1 Net Loss Narrows, Accelerates Phase 1 Trial of Ovarian Cancer Drug	04-10	MT
Transcript : Theratechnologies Inc., Q1 2024 Earnings Call, Apr 10, 2024	04-10
Theratechnologies Inc. Reports Earnings Results for the First Quarter Ended February 29, 2024	04-10	CI
Theratechnologies Brief: Citing Acceleration of Phase 1 trial of sudocetaxel zendusortide in advanced ovarian cancer with enrollment of next cohort of patients underway at higher dose level	04-10	MT
Theratechnologies Brief: FY2024 revenue guidance confirmed between US$87-$90 million and an Adjusted EBITDA in the range of $13-15 million	04-10	MT
Theratechnologies Brief: Q1 2024 consolidated revenue of US$16.2 Million; Says Report marks third consecutive quarter of near-flat-to-positive Adjusted EBITDA	04-10	MT
Theratechnologies Inc. Re-Affirms Earnings Guidance for the Fiscal Year 2024	04-10	CI
North American Morning Briefing : Traders Await -2-	04-10	DJ
Theratechnologies Inc. Preclinical Data Presentation At AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology? Oncology Platform	04-08	CI
Theratechnologies Inc. Appoints Elina Tea to its Board of Directors and as Member of the Company's Audit Committee	04-05	CI
Theratechnologies To Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology Platform	03-28	MT

Chart Theratechnologies Inc.

Duration

Period

More charts

Company Profile

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

Sector

Pharmaceuticals

Calendar

08/10/2024 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Theratechnologies Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.11 CAD

Average target price

8 CAD

Spread / Average Target

+279.15%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
THERATECHNOLOGIES INC.	-1.40%	71M
CSL LIMITED	+7.40%	101B
SAMSUNG BIOLOGICS CO.,LTD.	+7.76%	42.18B
BIOGEN INC.	-14.37%	32.26B
UCB	+80.86%	29.79B
BIOMARIN PHARMACEUTICAL INC.	-12.27%	16.06B
INCYTE CORPORATION	+2.33%	14.45B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-8.56%	12.01B
ALTEOGEN INC.	+182.74%	10.71B
SWEDISH ORPHAN BIOVITRUM AB	+4.12%	8.89B

Biopharmaceuticals

Theratechnologies Inc.

Equities

TH

CA88338H7040

Pharmaceuticals

Theratechnologies Reports on its Annual Meeting of Shareholders

EPS Revisions